183 related articles for article (PubMed ID: 30635687)
1. Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.
Malyshkina A; Littwitz-Salomon E; Sutter K; Ross JA; Paschen A; Windmann S; Schimmer S; Dittmer U
Cancer Immunol Immunother; 2019 Mar; 68(3):479-488. PubMed ID: 30635687
[TBL] [Abstract][Full Text] [Related]
2. Fas Ligand-mediated cytotoxicity of CD4+ T cells during chronic retrovirus infection.
Malyshkina A; Littwitz-Salomon E; Sutter K; Zelinskyy G; Windmann S; Schimmer S; Paschen A; Streeck H; Hasenkrug KJ; Dittmer U
Sci Rep; 2017 Aug; 7(1):7785. PubMed ID: 28798348
[TBL] [Abstract][Full Text] [Related]
3. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
4. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.
Robertson SJ; Messer RJ; Carmody AB; Mittler RS; Burlak C; Hasenkrug KJ
J Immunol; 2008 Apr; 180(8):5267-74. PubMed ID: 18390707
[TBL] [Abstract][Full Text] [Related]
5. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
6. Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.
Knuschke T; Rotan O; Bayer W; Sokolova V; Hansen W; Sparwasser T; Dittmer U; Epple M; Buer J; Westendorf AM
Retrovirology; 2016 Apr; 13():24. PubMed ID: 27076190
[TBL] [Abstract][Full Text] [Related]
7. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM
mBio; 2021 Feb; 12(1):. PubMed ID: 33531395
[TBL] [Abstract][Full Text] [Related]
8. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
9. Role of natural killer cells in resistance against friend retrovirus-induced leukemia.
Iwanami N; Niwa A; Yasutomi Y; Tabata N; Miyazawa M
J Virol; 2001 Apr; 75(7):3152-63. PubMed ID: 11238842
[TBL] [Abstract][Full Text] [Related]
10. B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection.
Moore TC; Gonzaga LM; Mather JM; Messer RJ; Hasenkrug KJ
mBio; 2017 Aug; 8(4):. PubMed ID: 28765225
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.
Manzke N; Akhmetzyanova I; Hasenkrug KJ; Trilling M; Zelinskyy G; Dittmer U
J Virol; 2013 Jun; 87(11):6306-13. PubMed ID: 23536666
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection.
Zelinskyy G; Kraft AR; Schimmer S; Arndt T; Dittmer U
Eur J Immunol; 2006 Oct; 36(10):2658-70. PubMed ID: 16981182
[TBL] [Abstract][Full Text] [Related]
13. Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus.
Robertson SJ; Ammann CG; Messer RJ; Carmody AB; Myers L; Dittmer U; Nair S; Gerlach N; Evans LH; Cafruny WA; Hasenkrug KJ
J Virol; 2008 Jan; 82(1):408-18. PubMed ID: 17959678
[TBL] [Abstract][Full Text] [Related]
14. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
15. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
16. Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8
Knuschke T; Rotan O; Bayer W; Kollenda S; Dickow J; Sutter K; Hansen W; Dittmer U; Lang KS; Epple M; Buer J; Westendorf AM
Front Immunol; 2018; 9():614. PubMed ID: 29740425
[TBL] [Abstract][Full Text] [Related]
17. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
18. Effects of Friend Virus Infection and Regulatory T Cells on the Antigen Presentation Function of B Cells.
Moore TC; Messer RJ; Gonzaga LM; Mather JM; Carmody AB; Bayer W; Littwitz-Salomon E; Dittmer U; Hasenkrug KJ
mBio; 2019 Jan; 10(1):. PubMed ID: 30670616
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.
Akhmetzyanova I; Zelinskyy G; Schimmer S; Brandau S; Altenhoff P; Sparwasser T; Dittmer U
Cancer Immunol Immunother; 2013 Feb; 62(2):257-71. PubMed ID: 22890822
[TBL] [Abstract][Full Text] [Related]
20. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
